Core Insights - Bio-Path Holdings, Inc. reported promising preclinical results for BP1001-A, indicating its potential as a treatment for obesity and related metabolic diseases in Type 2 diabetes patients [1][3] - The company plans to conduct a final preclinical mouse model study in the first half of 2025 and aims to file an Investigational New Drug (IND) application by the end of 2025 to initiate a Phase 1 clinical trial [2][3] Company Overview - Bio-Path Holdings is a biotechnology company focused on developing its proprietary DNAbilize® technology, which has led to a pipeline of RNAi nanoparticle drugs [4] - The lead product candidate, prexigebersen (BP1001), is currently in a Phase 2 study for blood cancers, while BP1001-A is being evaluated for both solid tumors and obesity-related metabolic diseases [4] Preclinical Study Results - Recent studies demonstrated that BP1001-A can restore insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models, which is crucial for treating obesity in Type 2 diabetes patients [3][7] - BP1001-A downregulates Grb2 expression, which is linked to increased insulin sensitivity and lower blood glucose levels in Type 2 diabetes patients [3][7] Future Plans - The company is preparing for the final stage of preclinical testing using a mouse model to assess BP1001-A's impact on weight, insulin sensitivity, and glucose tolerance [2][3] - If the upcoming studies are successful, Bio-Path anticipates filing an IND application in 2025 to begin human clinical trials [2][3]
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients